Scheme 1
Illustration of the biomimetic oxygen-delivery nanoparticles (CmPF) used for homologous targeting and improving oxygen concentration within the tumor microenvironment, thereby enhancing the immunotherapy efficacy through improved activation of immune cells. 68Ga-NOTA-GZP PET/CT imaging was performed to evaluate the combination treatment response in vivo. CmPF was injected intravenously into LLC xenografts followed by administration of the combination therapy. Tumor volume was measured to assess the therapeutic efficacy enhancement. PFTBA: perfluorotributylamine, HSA: human serum albumin, PF: HSA-PFTBA, CmPF: cancer cell membrane-coated HSA-doped PFTBA, PET/CT: positron emission tomography/computed tomography, Car: carboplatin, PD-1: anti-mouse PD-1